Efficacy of different dosage levels and administration routes of tilmicosin in a natural outbreak of infectious bovine keratoconjunctivitis (Pinkeye)

Abstract

A total of 120 purebred Hereford cattle were selected from a herd on a ranch in Argentina that had a severe outbreak of infectious bovine keratoconjunctivitis (IBK, pinkeye) caused by Moraxella bovis. The animals were separated into six treatment groups: a nonmedicated control group, a group that received oxytetracycline at 300 mg injected intrapalpebrally, and four groups that received tilmicosin (Micotil®, Elanco Animal Health, Indianapolis, IN; one group injected intrapalpebrally at 300 mg and three groups injected subcutaneously at 2.5, 5, and 10 mg/kg body weight, respectively). Animals were individually observed for resolution of lesions associated with IBK (ocular discharge, blepharospasm, and corneal lesions) every 7 days for 3 weeks. Corneal improvement was significantly better (P ‰ .05) for all doses and for either route of injection for tilmicosin compared with no treatment or treatment with oxytetracycline. Tilmicosin given subcutaneously demonstrated a significant (P ‰ .05) dose response for overall improvement (one or more score improved, none worsened). Tilmicosin given subcutaneously at 10 mg/kg was significantly more effective than tilmicosin at 2.5 mg/kg, oxytetracycline, and no treatment. Results for tilmicosin at 5 mg/kg were numerically better than no treatment, and tilmicosin at 10 mg/kg was numerically better than the drug given by intrapalpebral injection. Tilmicosin given by subcutaneous injection at 5 or 10 mg/kg was effective against IBK under the conditions of this study. © 2001-2010 MediMedia Animal Health.